In March, we reported that Prestige BioPharma had announced positive safety and efficacy results in a Phase III study for HD201.

On February 2, 2025, Shanghai Henlius Biotech, Inc. ("Henlius") announced FDA acceptance of the Biologics License Application (BLA) for HLX11...

Stelis Biopharma Receives Positive Recommendation for FORSTEO Biosimilar in Europe.

On April 26, 2026, Sun Pharmaceutical Industries Limited (“Sun Pharma”) and Organon & Co. (“Organon”) announced an agreement for Sun Pharma to acquire all outstanding shares of Organon...

Businesses that award shares, options or other securities to UK employees, directors or officer holders need to be aware of the July 6 deadline to submit an Employment Related Securities (ERS)...

Alvotech recently submitted a Citizen Petition to the FDA requesting that the agency refuse to license any ustekinumab biosimilar as interchangeable with STELARA if it is manufactured using a Chinese hamster ovary ("CHO")...

On November 7, 2022, the UK's Medicines and Healthcare Products Regulatory Agency ("MHRA") updated its "Guidance on the licensing of biosimilar products"...

In 2017, three indirect-purchaser antitrust class actions were filed against Johnson & Johnson and Janssen Biotech, Inc., alleging that they engaged in anticompetitive conduct...

FINRA recently published Regulatory Notice 22-10 reminding firms of the scope of Rule 3110 (Supervision) and the potential liability of ...

The suit alleges that the defendant failed to correct significant deficiencies in its remittance transfer systems that were identified during a CFPB examination in 2014 and re-examination in 2019.

On July 21, 2025, the Consumer Financial Protection Bureau (CFPB) announced that it had terminated its October 2024 consent order with a Florida-based credit union.

In Colorado, it is unlawful for a company that provides debt management services to also lend money or provide credit to the same consumer.

On October 26, 2022, the U.S. Securities and Exchange Commission (the "SEC") adopted regulations implementing Section 10D of the Securities Exchange Act of 1934...

On January 2, 2024, the Federal Trade Commission (FTC) announced it had reached a settlement with a California-based lead generator resolving allegations...

While annual meeting season for calendar year-end companies is heading towards the home stretch, numerous companies are still filing additional proxy materials.

In a Friday appearance on Fox Business, SEC Chairman Paul Atkins signaled that the Securities and Exchange Commission is increasingly focused on curbing the influence of proxy advisory firms.

The SEC announced that the EDGAR system will be closed on both Tuesday, December 24, 2024 and Wednesday, December 25, 2024. December 25 is a federal holiday and December 24 will be treated...

Every year public companies need to disclose the voting standards applicable to proposals included in their annual meeting proxy statements.

Our Public Company Advisory Practice has been seeing an increase in situations where clients are having difficulty reaching a quorum for an annual or special meeting or in securing enough votes to pass a proposal.

On March 20, 2025, the staff of the SEC's Division of Corporation Finance issued revised Securities Act Forms C&DI Question 114.05 indicating that non-automatically effective registration statements on Form S-3 may now be filed and declared effective after an issuer has filed its Form 10-K but prior to filing its Part III information that will be incorporated by reference into the Form 10-K.